Our Team
The people who research, write, and review every article on Myostatin Inhibitors Hub.
Myostatin Inhibitors Hub Editorial
Research & Writing
Our in-house editorial team writes the bulk of the site. Every article is grounded in primary literature on the myostatin-activin pathway and trial data from current and pipeline myostatin inhibitors. Drafts are checked against the published evidence before they go live.
Clinical Review
Medical & Pharmacology Review
Articles touching dosing, side effects, interactions, or contraindications are reviewed by a clinician with prescribing experience in metabolic and musculoskeletal medicine. Reviewer initials and the review date appear on the article when this step has been completed.
Trial & Evidence Review
Clinical Trial Data
Articles that cite trial outcomes — bimagrumab, apitegromab, taldefgrobep alfa, follistatin-based candidates, and others — are cross-checked against the original publications and trial registries. We flag press-release framing that doesn't match the underlying data.
Our Commitment
We don't publish anything we wouldn't hand to a friend asking the same question. See our editorial guidelines for how we research, source, and review every article.